Pfizer Recalls Dopamine Hydrochloride Injection Due to Sterility Concerns
Pfizer is recalling specific lots of Dopamine Hydrochloride Injection due to a lack of assurance of sterility. The affected product is distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a sterile injectable drug with a lack of assurance of sterility falls under the 'Severe' category (Score 4), as it carries a significant risk of serious injury or death if contaminated, even if specific hospitalization reports are not yet detailed in the snippet.
Plain-English summary
Pfizer is recalling Dopamine Hydrochloride Injection, USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose vials. The recall is limited to Lot # NL5230 with an expiration date of 10/2027. The product is distributed by Hospira, Inc., and is available under NDC 0409-5820-11 (vial) and 0409-5820-01 (carton).
The recall was initiated due to a lack of assurance of sterility. This means the manufacturer cannot guarantee that the product is free from microbial contamination. The affected units were distributed nationwide in the United States.
Healthcare providers and facilities should stop using the affected lot immediately and contact Pfizer or Hospira for instructions on how to return or dispose of the product. Patients should consult their healthcare provider if they have received this specific medication.
The recalled product
- Product
- DOPAMINE HYDROCHLORIDE (DOPAMINE HYDROCHLORIDE)
- Brand
- DOPAMINE HYDROCHLORIDE
- Manufacturer
- Pfizer
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # NL5230
- Exp Date:10/2027
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Pfizer
See all →- HighLevoxyl 50 microgram levothyroxine tablets recalled as a subpotent drug
FDA (Drugs) · 2025-08-20
- SevereDrug recall: Bleomycin injection vials recalled due to glass contamination
FDA (Drugs) · 2024-01-31
- SeverePfizer Recalls Daptomycin Injection Due to Microbial Contamination
FDA (Drugs) · 2018-08-08
- HighPfizer Recalls PureSilk Shave Gel for Women Due to Rupture Risk
CPSC · 1996-07-02
Same hazard · sterility
See all →- SevereAVID Medical Recalls Haylard Basic Biopsy Trays Due to Sterility Concerns
FDA (Devices) · 2026-09-23
- SevereAVID Medical Recalls Haylard 18G Single Shot Epi Trays Due to Sterility Concerns
FDA (Devices) · 2026-09-23
- SevereAVID Medical Recalls Biopsy Kits Due to Sterility Concerns
FDA (Devices) · 2026-09-23
- CriticalAmerican Regent Recalls Epinephrine Vials Due to Particulate Matter
FDA (Drugs) · 2026-09-16
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- SeverePfizer Recalls Hydromorphone Hydrochloride Injection Vials Due to Non-Sterility
FDA (Drugs) · 2018-03-21
- SevereHospira Recalls Diazepam Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-04
- HighSpectra lidocaine ampules recalled over lack of sterility assurance
FDA (Drugs) · 2026-06-10
- SevereSun Pharmaceutical Recalls Doxorubicin Hydrochloride Injection Due to Sterility Concerns
FDA (Drugs) · 2018-01-31
- CriticalPfizer Recalls Hydromorphone Hydrochloride Injection Due to Non-Sterility Concerns
FDA (Drugs) · 2018-03-21
- SevereHospira Recalls Furosemide Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2013-03-06